SMT201500097B - Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a - Google Patents
Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2aInfo
- Publication number
- SMT201500097B SMT201500097B SM201500097T SM201500097T SMT201500097B SM T201500097 B SMT201500097 B SM T201500097B SM 201500097 T SM201500097 T SM 201500097T SM 201500097 T SM201500097 T SM 201500097T SM T201500097 B SMT201500097 B SM T201500097B
- Authority
- SM
- San Marino
- Prior art keywords
- adenosine
- antagonists
- receptor
- aminopyrimidine derivatives
- aminopyrimidine
- Prior art date
Links
- 150000005007 4-aminopyrimidines Chemical class 0.000 title 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 title 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201030489A ES2365960B1 (es) | 2010-03-31 | 2010-03-31 | Nuevos antagonistas de los receptores de adenosina. |
PCT/IB2011/000664 WO2011121418A1 (fr) | 2010-03-31 | 2011-03-29 | Dérivés de 4-aminopyrimidine et leur utilisation en tant qu'antagonistes des récepteurs de l'adénosine a2a |
Publications (1)
Publication Number | Publication Date |
---|---|
SMT201500097B true SMT201500097B (it) | 2015-07-09 |
Family
ID=44120157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SM201500097T SMT201500097B (it) | 2010-03-31 | 2015-04-17 | Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a |
Country Status (22)
Country | Link |
---|---|
US (1) | US8796284B2 (fr) |
EP (1) | EP2552909B1 (fr) |
JP (1) | JP5725383B2 (fr) |
KR (1) | KR101441781B1 (fr) |
CN (1) | CN102892761B (fr) |
AU (1) | AU2011234144B2 (fr) |
BR (1) | BR112012024870B1 (fr) |
CA (1) | CA2795009C (fr) |
CY (1) | CY1116328T1 (fr) |
DK (1) | DK2552909T3 (fr) |
EA (1) | EA021565B1 (fr) |
ES (2) | ES2365960B1 (fr) |
HR (1) | HRP20150366T1 (fr) |
ME (1) | ME02100B (fr) |
MX (1) | MX2012011240A (fr) |
PL (1) | PL2552909T3 (fr) |
PT (1) | PT2552909E (fr) |
RS (1) | RS53939B1 (fr) |
SI (1) | SI2552909T1 (fr) |
SM (1) | SMT201500097B (fr) |
WO (1) | WO2011121418A1 (fr) |
ZA (1) | ZA201207259B (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170647A1 (fr) * | 2011-06-09 | 2012-12-13 | Assia Chemical Industriew Ltd. | Procédé pour la préparation d'étravirine et intermédiaires dans la synthèse de celle-ci |
PL2922828T3 (pl) | 2012-11-21 | 2020-12-28 | Ptc Therapeutics, Inc. | Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka |
ES2480341B1 (es) * | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
TWI692477B (zh) | 2013-08-30 | 2020-05-01 | 美商Ptc治療公司 | 經取代嘧啶bmi-1抑制劑 |
US10584115B2 (en) | 2013-11-21 | 2020-03-10 | Ptc Therapeutics, Inc. | Substituted pyridine and pyrazine BMI-1 inhibitors |
CN103626741A (zh) * | 2013-11-26 | 2014-03-12 | 苏州大学 | 具有腺苷受体拮抗剂活性的杂环氨基嘧啶化合物 |
CN103664908A (zh) * | 2013-12-10 | 2014-03-26 | 苏州大学 | 一种具有腺苷受体拮抗活性的氨基嘧啶杂环化合物 |
EP3324974B1 (fr) * | 2015-07-24 | 2022-06-08 | University Of Louisville Research Foundation, Inc. | Composés, compositions, procédés pour le traitement de maladies et procédés pour la préparation de composés |
KR102226100B1 (ko) * | 2015-08-11 | 2021-03-10 | 노파르티스 아게 | 암의 치료에 사용하기 위한 5-브로모-2,6-디-(1h-피라졸-1-일)피리미딘-4-아민 |
CA2994918C (fr) * | 2015-08-11 | 2024-03-19 | Novartis Ag | 5-bromo-2,6-di-(1h-pyrazol-1-yl)pyrimidin-4-amine pour utilisation dans le traitement du cancer |
AU2017247008B2 (en) | 2016-04-06 | 2022-04-07 | Noxopharm Limited | Isoflavonoid composition with improved pharmacokinetics |
JP2019513826A (ja) | 2016-04-06 | 2019-05-30 | ノクソファーム リミティド | 放射線療法の改善 |
CN106543416A (zh) * | 2016-10-21 | 2017-03-29 | 新疆大学 | 含嘧啶的聚合物在dmf溶液中检测硫酸浓度方面的应用 |
WO2018146612A1 (fr) | 2017-02-10 | 2018-08-16 | Novartis Ag | 1- (4-amino-5-bromo-6-(1 h-pyrazol-1-yl) pyrimidine-2-yl) -1 h-pyrazol-4-ol et son utilisation dans le traitement du cancer |
JOP20190279A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة |
EP3642240A1 (fr) | 2017-06-22 | 2020-04-29 | Novartis AG | Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes |
CN118307674A (zh) | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
CN107286146B (zh) * | 2017-07-05 | 2020-07-31 | 上海肇钰医药科技有限公司 | 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途 |
WO2019099838A1 (fr) | 2017-11-16 | 2019-05-23 | Novartis Ag | Polythérapies |
TW201925782A (zh) | 2017-11-30 | 2019-07-01 | 瑞士商諾華公司 | 靶向bcma之嵌合抗原受體及其用途 |
CA3090922A1 (fr) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosage avec un compose azolopyrimidine |
WO2019178269A2 (fr) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Anticorps qui se lient à cd39 et leurs utilisations |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2019232244A2 (fr) | 2018-05-31 | 2019-12-05 | Novartis Ag | Molécules d'anticorps anti-cd73 et leurs utilisations |
JP7398396B2 (ja) | 2018-06-01 | 2023-12-14 | ノバルティス アーゲー | Bcmaに対する結合分子及びその使用 |
CA3100923A1 (fr) | 2018-06-04 | 2019-12-12 | Exscientia Ltd | Composes de pyrazolopyrimidine utilises en tant qu'antagonistes du recepteur de l'adenosine |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
TWI728404B (zh) * | 2018-07-13 | 2021-05-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 一種1,2,4-三-3-胺類衍生物的晶型及製備方法 |
AU2019340402A1 (en) | 2018-08-17 | 2021-03-25 | Ptc Therapeutics, Inc. | Method for treating pancreatic cancer |
US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
JP2022503879A (ja) * | 2018-09-27 | 2022-01-12 | アイテオ ベルギウム エスエー | がん治療におけるentファミリートランスポーター阻害剤の使用及びそのアデノシン受容体アンタゴニストとの組み合わせ |
BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
WO2020128637A1 (fr) | 2018-12-21 | 2020-06-25 | Novartis Ag | UTILISATION D'ANTICORPS DE LIAISON À IL-1β DANS LE TRAITEMENT D'UN CANCER MSI-H |
US20220056123A1 (en) | 2018-12-21 | 2022-02-24 | Novartis Ag | Use of il-1beta binding antibodies |
US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
CN113329792B (zh) | 2019-02-15 | 2024-06-28 | 诺华股份有限公司 | 取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
EP4034559A1 (fr) | 2019-09-25 | 2022-08-03 | Surface Oncology, Inc. | Anticorps anti-il-27 et leurs utilisations |
CA3165399A1 (fr) | 2019-12-20 | 2021-06-24 | Novartis Ag | Utilisations d'anticorps anti-tgf-betas et inhibiteurs de point de controle pour le traitement des maladies proliferatives |
CN115996927A (zh) | 2020-02-26 | 2023-04-21 | Iteos比利时公司 | 作为ENT抑制剂用于治疗癌症的嘧啶并[5,4-d]嘧啶衍生物及其与腺苷受体拮抗剂的组合 |
CN113748110B (zh) * | 2020-03-16 | 2024-05-14 | 上海海雁医药科技有限公司 | 取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
CN113429410B (zh) * | 2020-03-23 | 2022-10-04 | 上海海雁医药科技有限公司 | 多杂环取代的嘧啶或吡啶胺衍生物、其组合物及医药上的用途 |
MX2022011826A (es) * | 2020-03-27 | 2022-10-18 | Dong A St Co Ltd | Derivados de aminopirimidina y su uso como moduladores del receptor de hidrocarburos de arilo. |
EP4125870A1 (fr) | 2020-03-30 | 2023-02-08 | Noxopharm Limited | Méthodes de traitement d'une inflammation associée à une infection |
IL297127A (en) | 2020-04-07 | 2022-12-01 | iTeos Belgium SA | Macrocyclic diamine derivatives as ent inhibitors for cancer treatment and their combination with adenosine receptor antagonists |
CN111362939B (zh) * | 2020-04-26 | 2021-08-03 | 山东梅奥华卫科技有限公司 | 一种帕布昔利布母核结构化合物的制备方法 |
CA3182346A1 (fr) | 2020-06-23 | 2021-12-30 | Novartis Ag | Schema posologique comprenant des derives de 3-(1-oxoisoindoline-2-yl) piperidine-2,6-dione |
US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EP4240491A1 (fr) | 2020-11-06 | 2023-09-13 | Novartis AG | Molécules de liaison à cd19 et utilisations associées |
WO2022162569A1 (fr) | 2021-01-29 | 2022-08-04 | Novartis Ag | Régimes posologiques d'anticorps anti-cd73 et anti-entpd2 et leurs utilisations |
CN117136242A (zh) | 2021-02-17 | 2023-11-28 | Iteos比利时公司 | 化合物、组合物及其治疗方法 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN117794913A (zh) * | 2021-09-15 | 2024-03-29 | 上海海雁医药科技有限公司 | 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用 |
KR20240013997A (ko) | 2022-07-22 | 2024-01-31 | 서울대학교산학협력단 | 아데노신 수용체에 작용하는 리간드 내지 이를 포함하는 비만 예방, 개선 또는 치료용 조성물 |
WO2024134541A1 (fr) | 2022-12-20 | 2024-06-27 | iTeos Belgium SA | Composés hétérocycliques utilisés en tant qu'inhibiteurs d'ent et composés destinés à être utilisés dans le traitement de cancers |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2315736A1 (fr) | 1998-01-05 | 1999-07-15 | Eisai Co., Ltd. | Derives de purine et antagonistes du recepteur a2 d'adenosine comme moyens preventif ou therapeutique du diabete sucre |
AU778450B2 (en) | 1999-07-02 | 2004-12-09 | Eisai R&D Management Co., Ltd. | Fused imidazole compounds and remedies for diabetes mellitus |
ATE293962T1 (de) * | 2000-02-25 | 2005-05-15 | Hoffmann La Roche | Adenosin-rezeptor modulatoren |
JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
TWI330183B (fr) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
BRPI0417478A (pt) * | 2003-12-15 | 2007-05-08 | Almirall Prodesfarma Ag | 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina |
EP1894930A4 (fr) * | 2005-06-23 | 2010-06-23 | Kyowa Hakko Kirin Co Ltd | Dérivé du thiazole |
EP2121662A1 (fr) * | 2006-12-04 | 2009-11-25 | Neurocrine Biosciences, Inc. | Pyrimidines substituées en tant qu'antagonistes des récepteurs de l'adénosine |
US20080221103A1 (en) * | 2007-03-09 | 2008-09-11 | Orchid Research Laboratories Ltd. | New heterocyclic compounds |
EP2132197A2 (fr) * | 2007-03-21 | 2009-12-16 | Almirall, S.A. | Pyrimidines substituées utilisées comme antagonistes des récepteurs de l'adénosine |
WO2009032694A1 (fr) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Pyrimidine substituée par amino, dérivés de pyrollopyridine et de pyrazolopyrimidine utilisés en tant qu'inhibiteurs de la kinase et dans le traitement de troubles prolifératifs et de maladies liées à l'angiogenèse |
-
2010
- 2010-03-31 ES ES201030489A patent/ES2365960B1/es active Active
-
2011
- 2011-03-29 ES ES11719879.6T patent/ES2534227T3/es active Active
- 2011-03-29 SI SI201130458T patent/SI2552909T1/sl unknown
- 2011-03-29 EP EP11719879.6A patent/EP2552909B1/fr active Active
- 2011-03-29 US US13/636,624 patent/US8796284B2/en active Active
- 2011-03-29 BR BR112012024870-7A patent/BR112012024870B1/pt active IP Right Grant
- 2011-03-29 EA EA201201343A patent/EA021565B1/ru not_active IP Right Cessation
- 2011-03-29 DK DK11719879.6T patent/DK2552909T3/en active
- 2011-03-29 PT PT117198796T patent/PT2552909E/pt unknown
- 2011-03-29 JP JP2013501975A patent/JP5725383B2/ja active Active
- 2011-03-29 KR KR1020127028611A patent/KR101441781B1/ko active IP Right Grant
- 2011-03-29 CA CA2795009A patent/CA2795009C/fr active Active
- 2011-03-29 ME MEP-2015-55A patent/ME02100B/me unknown
- 2011-03-29 RS RS20150254A patent/RS53939B1/en unknown
- 2011-03-29 PL PL11719879T patent/PL2552909T3/pl unknown
- 2011-03-29 AU AU2011234144A patent/AU2011234144B2/en active Active
- 2011-03-29 MX MX2012011240A patent/MX2012011240A/es active IP Right Grant
- 2011-03-29 WO PCT/IB2011/000664 patent/WO2011121418A1/fr active Application Filing
- 2011-03-29 CN CN201180022061.2A patent/CN102892761B/zh active Active
-
2012
- 2012-09-27 ZA ZA2012/07259A patent/ZA201207259B/en unknown
-
2015
- 2015-03-30 HR HRP20150366TT patent/HRP20150366T1/hr unknown
- 2015-04-16 CY CY20151100352T patent/CY1116328T1/el unknown
- 2015-04-17 SM SM201500097T patent/SMT201500097B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
KR20130028732A (ko) | 2013-03-19 |
ZA201207259B (en) | 2013-09-25 |
JP5725383B2 (ja) | 2015-05-27 |
ES2365960A1 (es) | 2011-10-14 |
WO2011121418A9 (fr) | 2012-04-05 |
RS53939B1 (en) | 2015-08-31 |
WO2011121418A1 (fr) | 2011-10-06 |
ES2534227T3 (es) | 2015-04-20 |
CN102892761B (zh) | 2015-02-04 |
CY1116328T1 (el) | 2017-02-08 |
EA021565B1 (ru) | 2015-07-30 |
EP2552909A1 (fr) | 2013-02-06 |
CA2795009A1 (fr) | 2011-10-06 |
JP2013523711A (ja) | 2013-06-17 |
PL2552909T3 (pl) | 2015-08-31 |
DK2552909T3 (en) | 2015-04-13 |
HRP20150366T1 (hr) | 2015-05-22 |
AU2011234144B2 (en) | 2014-04-24 |
PT2552909E (pt) | 2015-04-23 |
EP2552909B1 (fr) | 2015-03-11 |
AU2011234144A1 (en) | 2012-10-25 |
BR112012024870B1 (pt) | 2020-11-17 |
EA201201343A1 (ru) | 2013-03-29 |
KR101441781B1 (ko) | 2014-09-17 |
CN102892761A (zh) | 2013-01-23 |
SI2552909T1 (sl) | 2015-06-30 |
MX2012011240A (es) | 2012-11-30 |
BR112012024870A2 (pt) | 2016-06-14 |
US20130053308A1 (en) | 2013-02-28 |
ME02100B (me) | 2015-10-20 |
US8796284B2 (en) | 2014-08-05 |
CA2795009C (fr) | 2016-06-21 |
ES2365960B1 (es) | 2012-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SMT201500097B (it) | Derivati di 4-amminopirimidina e loro uso come antagonsiti del recettore di adenosina a2a | |
SMT201500174B (it) | Derivati ossidati di triazolilpurine utili come li-ganti del recettore di adenosina a2a e loro utilizzo come medicinali | |
SMT201600226B (it) | Alcune amminopirimidine, loro composizioni e metodi per il loro uso | |
SMT201600198B (it) | Derivati di 1,2,4-triazina-4-ammina | |
CO7000776A2 (es) | Pirimidinas y triazinas fusionadas sustituidas y su uso | |
BR112014014547A2 (pt) | compostos antagonistas de e-selectina, composições e métodos de uso | |
SMT201700064B (it) | Antagonisti di d2, metodi di sintesi e metodi di uso | |
BR112012013148A2 (pt) | formulação farmacêutica e uso | |
BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
SMT201400001B (it) | Derivati pirazolici usati come antagonisti del recettore CCR4 | |
SMT201600078B (it) | Antagonista del recettore per cgrp | |
BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
BR112013009465A2 (pt) | compósitos reforçados com fibra, pré-forma axissimétrica continua para uso nos mesmos e respectivos métodos de produção | |
CO6930360A2 (es) | Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas preferentes del receptor de canabinoides 2 | |
IT1392249B1 (it) | Derivati di [(3-idrossi-4-piron-2-il)metil]-amina e loro uso come farmaci anti-neoplastici | |
SMT201500296B (it) | Antagonisti del recettore trpm8 | |
SMT201300077B (it) | Derivati di ciclopropilammide diretti al recettoredi istamina H3 | |
UY34160A (es) | Ligandos del receptor trpm8 y su uso en diversos tratamientos | |
ZA201104873B (en) | Quinazolinone derivatives useful as vanilloid antagonists | |
CO6781486A2 (es) | Compuestos y su uso | |
SMT201500293B (it) | Antagonisti del recettore toll-like 3 | |
SMT201400157B (it) | Derivati di 2-piridin-2-il-pirazol-3(2H)-one, loropreparazione e loro uso terapeutico | |
BR112013023575A2 (pt) | derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes | |
SMT201500067B (it) | Derivati di acilbenzene | |
IT1391175B1 (it) | Derivati del bifluorenilidene, loro preparazione e loro uso |